Language
English
Publication Date
6-12-2023
Journal
BMJ Open
DOI
10.1136/bmjopen-2022-071311
PMID
37308268
PMCID
PMC10277034
PubMedCentral® Posted Date
6-12-2023
PubMedCentral® Full Text Version
Post-print
Abstract
INTRODUCTION: Hyperkalaemia is common, life-threatening and often requires emergency department (ED) management; however, no standardised ED treatment protocol exists. Common treatments transiently reducing serum potassium (K
METHODS AND ANALYSIS: PLATINUM is a Phase 4, multicentre, randomised, double-blind, placebo-controlled study in participants who present to the ED at approximately 30 US sites. Approximately 300 adult participants with hyperkalaemia (K
ETHICS AND DISSEMINATION: A central Institutional Review Board (IRB) and Ethics Committee provided protocol approval (#20201569), with subsequent approval by local IRBs at each site, and participants will provide written consent. Primary results will be published in peer-reviewed manuscripts promptly following study completion.
Keywords
Adult, Humans, Albuterol, Ethics Committees, Research, Glucose, Hyperkalemia, Insulin, Clinical Trials, Phase IV as Topic, Randomized Controlled Trials as Topic, Multicenter Studies as Topic
Published Open-Access
yes
Recommended Citation
Rafique, Zubaid; Budden, Jeffrey; Quinn, Carol Moreno; et al., "Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalaemia Management (Platinum): Design of a Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study" (2023). Faculty and Staff Publications. 515.
https://digitalcommons.library.tmc.edu/baylor_docs/515